Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2005 Oct;43(10):5285-7.
doi: 10.1128/JCM.43.10.5285-5287.2005.

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

M K Hayden  1 , K Rezai, R A Hayes, K Lolans, J P Quinn, R A Weinstein
Affiliations
Case Reports

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

M K Hayden et al. J Clin Microbiol. 2005 Oct.

Abstract

Daptomycin is a new lipopeptide antibiotic that is rapidly bactericidal against Staphylococcus aureus. We report daptomycin resistance and treatment failure in 2 patients with osteomyelitis due to methicillin-resistant S. aureus. Disk diffusion susceptibility testing failed to detect resistance. Daptomycin at high concentration retained bactericidal activity against resistant isolates.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Time-kill experiments with representative daptomycin-susceptible and daptomycin-resistant methicillin-resistant Staphylococcus aureus isolates. (A) Daptomycin-susceptible isolate from patient 1. (B) Daptomycin-resistant isolate from patient 1. (C) Daptomycin-susceptible isolate from patient 2. (D) Daptomycin-resistant isolate from patient 2. Abbreviations: C, Growth control without daptomycin; 1× MIC, 2× MIC, and 4× MIC, daptomycin concentrations tested were equal to, twice, and four times higher than the MIC of daptomycin for the isolate, respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459. - PMC - PubMed
    1. Cubist Pharmaceuticals, Inc. 2003. Daptomycin (Cubicin) package literature. Cubist Pharmaceuticals, Inc., Lexington, Mass.
    1. Cubist Pharmaceuticals, Inc.. Daptomycin in the treatment of subjects with infective endocarditis or bacteremia due to S. aureus. ClinicalTrials.gov, identifier NCT00093067. [Online.] http://clinicaltrials.gov/show/NCT00093067.
    1. Mader, J. T., and K. Adams. 1989. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob. Agents Chemother. 33:689-692. - PMC - PubMed
    1. Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060. - PubMed

Publication types